Cited by 1,155Multiple Myeloma Research and TreatmentsBone health and treatmentsMultiple Sclerosis Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Open access

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, Harousseau, Jean-Luc·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114138

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS: Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114138

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citation
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citation

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 301–400 of 1,000

Current approaches for the treatment of multiple myeloma
Watanabe, R., Tokuhira, M., & Kizaki, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1294-z · Cited by 29
Multiple Myeloma : Recent Progress in Diagnosis and Treatment
Chou, T. (2012) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.52.149 · Cited by 28
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma
Mian, I., Milton, D. R., Shah, N. D., Nieto, Y. L., Popat, U., Kebriaei, P., Parmar, S., Oran, B., Shah, J. J., Manasanch, E. E., et al. (2016) · Cancer · doi:10.1002/cncr.30366 · Cited by 28
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma
Aldoss, I. T., Capelletti, M., Park, J., Sklavenitis‐Pistofidis, R., Pillai, R. K., Stiller, T., Sanchez, J. F., Forman, S. J., Ghobrial, I. M., & Krishnan, A. Y. (2018) · Leukemia · doi:10.1038/s41375-018-0213-y · Cited by 28
Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study
Peña, C., Riva, E., Schutz, N. P., Tarin-Arzaga, L. C., Martínez‐Cordero, H., Bove, V., Osorio, R., Chandía, M., Beltrán, C., Schulz, J., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1804558 · Cited by 28
MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
Brown, S., Sherratt, D., Hinsley, S., Flanagan, L. M., Roberts, S., Walker, K., Hall, A., Pratt, G., Messiou, C., Jenner, M. W., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046225 · Cited by 28
Cost‐effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma
Pandya, C. J., Hashmi, S. K., Khera, N., Gertz, M. A., Dispenzieri, A. A., Hogan, W. J., Siddiqui, M. A., Noyes, K., & Kumar, S. K. (2014) · Clinical Transplantation · doi:10.1111/ctr.12421 · Cited by 28
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion
Suzuki, K. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0684-5 · Cited by 28
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Harousseau, J., & Avet‐Loiseau, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.1331 · Cited by 28
Self-citation
Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
Kurtin, S. E., & Bilotti, E. (2013) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2013.4.5.11 · Cited by 27
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates
Terpos, E., Kastritis, E., Ntanasis‐Stathopoulos, I., Christoulas, D., Παπαθεοδώρου, Α., Eleutherakis‐Papaiakovou, E., Kanellias, N., Fotiou, D., Ziogas, D. C., Migkou, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25392 · Cited by 27
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27
Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
Ailawadhi, S., Swaika, A., Razavi, P., Yang, D., & Chanan-Khan, A. A. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.63 · Cited by 27
How lenalidomide is changing the treatment of patients with multiple myeloma
Dimopoulos, M. A., Terpos, E., & Niesvizky, R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.013 · Cited by 28
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
Reece, D. E., Song, K., LeBlanc, R., Mezzi, K., Olujohungbe, A., White, D. J., Zaman, F., & Belch, A. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0384 · Cited by 27
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance
Danhof, S., Schreder, M., Knop, S. T., Rasche, L., Strifler, S., Löffler, C., Gogishvili, T., Einsele, H., & Hudecek, M. (2017) · Haematologica · doi:10.3324/haematol.2017.178947 · Cited by 27
Adult Stem Cells and Medicine
Bozdağ, S. C., Yüksel, M. K., & Demirer, T. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_184 · Cited by 30
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Zweegman, S., Stege, C. A. M., Haukås, E., Schjesvold, F. H., Levin, M., Waage, A., Leys, R. B. L., Klein, S. K., Szatkowski, D., Axelsson, P., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.240374 · Cited by 27
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Introduction
Wayne, A. S., Giralt, S., Kröger, N. M., & Bishop, M. R. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.08.016 · Cited by 27
New Approaches to Management of Multiple Myeloma
Genadieva-Stavric, S., Cavallo, F., & Palumbo, A. P. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0276-6 · Cited by 27
Myeloma: Classification and Risk Assessment
Fonseca, R., & Monge, J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.002 · Cited by 26
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method
Manasanch, E. E., Salem, D., Yuan, C. M., Tageja, N., Bhutani, M., Kwok, M., Kazandjian, D. G., Carter, G., Steinberg, S. M., Zuchlinski, D., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.955020 · Cited by 26
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective
Desai, M., Newberry, K. J., Ou, Z., Wang, M. L., & Zhang, L. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532124 · Cited by 26
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 26
Managing multiple myeloma in elderly patients
Diamond, E., Lahoud, O. B., & Landau, H. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1365859 · Cited by 26
Ixazomib: a novel drug for multiple myeloma
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1518129 · Cited by 27
Current Treatment for Multiple Myeloma
Avigan, D., & Rosenblatt, J. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1407442 · Cited by 26
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Meseha, M., Hoffman, J. E., Kazandjian, D. G., Landgren, O., & Diamond, B. T. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01537-2 · Cited by 25
Current therapeutic strategies for multiple myeloma
Torimoto, Y., Shindo, M., Ikuta, K., & Kohgo, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0826-3 · Cited by 25
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus
Rivellese, F., Manou-Stathopoulou, S., Mauro, D., Goldmann, K., Pyne, D., Rajakariar, R., Gordon, P., Schafer, P. H., Bombardieri, M., Pitzalis, C., et al. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000445 · Cited by 25
Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7900 · Cited by 25
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma
Parmar, S., Bookout, R., Shapiro, J., Tombleson, R. L., Perkins, J., Kim, J., Yue, B., Tomblyn, M., Alsina, M., & Nishihori, T. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.56 · Cited by 25
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma
Iriuchishima, H., Ozaki, S., Konishi, J. S., Matsumoto, M., Murayama, K., Nakamura, F., Yamamoto, G., Handa, H., Saitoh, T., Nagura, E., et al. (2015) · Acta Haematologica · doi:10.1159/000439424 · Cited by 25
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Hoering, A., Durie, B. G. M., Wang, H., & Crowley, J. J. (2017) · Future Oncology · doi:10.2217/fon-2016-0504 · Cited by 25
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
Tan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 25
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Hari, P., Mateos, M., Abonour, R., Knop, S. T., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D. S. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.122 · Cited by 24
Self-citation
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma
Patel, P. R., Oh, A. L., Koshy, M., Sweiss, K. I., Saraf, S. L., Quigley, J. G., Khan, I., Mahmud, N., Hacker, E. D., Ozer, H., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1390231 · Cited by 24
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
Rossmann, E. D., Österborg, A., Löfvenberg, E., Choudhury, A., Forssmann, U., von Heydebreck, A., Schröder, A., & Mellstedt, H. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29918 · Cited by 24
Role of thalidomide in the treatment of patients with multiple myeloma
Morgan, G. J., & Davies, F. E. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.012 · Cited by 24
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 25
Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports
Le, T. X., Wolf, J. L., Peralta, C. A., & Webber, A. B. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.023 · Cited by 24
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Michallet, M., Chapuis‐Cellier, C., Dejoie, T., Lombard, C., Caillon, H., Sobh, M. A. K., Moreau, P., Attal, M., & Avet‐Loiseau, H. (2017) · Leukemia · doi:10.1038/leu.2017.209 · Cited by 25
Self-citation
Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma
Huskey, J. L., Heilman, R. L., Khamash, H. A., & Fonseca, R. (2018) · Transplantation · doi:10.1097/tp.0000000000002449 · Cited by 24
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
Martino, M. V., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P. F., et al. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1634541 · Cited by 24
Stem-cell transplantation in multiple myeloma: how far have we come?
Soekojo, C. Y., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719888111 · Cited by 24
Newly Diagnosed Myeloma in 2020
Moreau, P., Touzeau, C., Vij, R., Goldsmith, S. R., & Rosko, A. E. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280221 · Cited by 24
Self-citation
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
Rosenberg, A. S., Brunson, A. M., Tuscano, J. M., Jonas, B. A., Hoeg, R. T., Wun, T., & Keegan, T. H. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00400-4 · Cited by 24
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents
Gertz, M. A., Terpos, E., Dispenzieri, A. A., Kumar, S. K., Shah, R., Orlowski, R. Z., Kastritis, E., Dimopoulos, M. A., & Shah, J. J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.970543 · Cited by 24
Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
Zou, Y., Sheng, Z., Niu, S., Wang, H., Yu, J., & Xu, J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.774393 · Cited by 24
Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
Holstein, S. A., Richardson, P. G. G., Laubach, J. P., & McCarthy, P. L. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.026 · Cited by 23
Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
Reece, D. E., Kouroukis, C. T., LeBlanc, R., Sébag, M., Song, K., & Ashkenas, J. (2012) · Advances in Hematology · doi:10.1155/2012/621958 · Cited by 23
Autologous hematopoietic cell transplantation: An update for clinicians
Hamadani, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.952662 · Cited by 23
Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades
Bhatt, V. R., Loberiza, F. R., Jing, H., Bociek, R. G., Bierman, P. J., Maness, L. J., Vose, J. M., Armitage, J. O., & Akhtari, M. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.024 · Cited by 23
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma
Cornell, R. F., D’Souza, A., Kassim, A. A., Costa, L. J., Innis-Shelton, R. D., Zhang, M., Huang, J., Abidi, M. H., Aiello, J., Akpek, G., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.011 · Cited by 23
Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 25
Plasma Cell Tumors
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy
Wudhikarn, K., Padrnos, L. J., Lasho, T. L., LaPlant, B. R., Kumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Rajkumar, S. V., Gertz, M. A., Mangaonkar, A. A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26125 · Cited by 22
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
Barnell, E. K., Skidmore, Z. L., Newcomer, K. F., Chavez, M., Campbell, K. M., Cotto, K. C., Spies, N. C., Ruzinova, M. B., Wang, T., Abro, B., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007496 · Cited by 24
Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Banerjee, R. K., Poh, C., Hirayama, A. V. V., Gauthier, J., Cassaday, R. D., Shadman, M. S., Cowan, A. J., Till, B. G., Green, D. J., Kiem, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012336 · Cited by 22
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Pasvolsky, O., Wang, Z., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., Nieto, Y. L., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01062-2 · Cited by 22
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115
Sanchorawala, V., Hoering, A., Seldin, D. C., Finn, K. T., Fennessey, S. A., Sexton, R. E., Mattar, B. I., Safah, H. F., Holmberg, L., Dean, R. M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.98 · Cited by 22
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma
Martino, M. V., Olivieri, A., Offidani, M., Vigna, E., Moscato, T., Fedele, R., Montanari, M., Console, G., Gentile, M., Messina, G., et al. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.788643 · Cited by 22
Bortezomib and lenalidomide as front-line therapy for multiple myeloma
Zou, Y., Lin, M., Sheng, Z., & Niu, S. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.847935 · Cited by 22
Differential effects of lenalidomide during plasma cell differentiation
Jourdan, M., Cren, M., Schafer, P. H., Robert, N., Duperray, C., Vincent, L., Céballos, P., Cartron, G., Rossi, J., Moreaux, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8581 · Cited by 23
Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons
Avet‐Loiseau, H. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159088 · Cited by 22
Self-citation
Current Review on High-Risk Multiple Myeloma
Chan, H. S. H., Chen, C. I., & Reece, D. E. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0368-z · Cited by 22
Diagnosis and management of neuropathies associated with plasma cell dyscrasias
E, E. R. P., Marks, D. K., & Raza, S. (2017) · Hematological Oncology · doi:10.1002/hon.2417 · Cited by 23
Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation
Soiffer, R. J., & Chen, Y. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009894 · Cited by 22
Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018
Wang, J., Lv, C., Zhou, M., Xu, J., Chen, B., & Wan, Y. (2022) · Cancers · doi:10.3390/cancers14194919 · Cited by 22
Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 22
Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma
Fall, D. J., Stessman, H. A. F., Patel, S. S., Sachs, Z., Ness, B. G. V., Baughn, L. B., & Linden, M. A. (2014) · Journal of Cancer · doi:10.7150/jca.9864 · Cited by 21
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis
Wang, X., Li, Y., & Yan, X. (2016) · BioMed Research International · doi:10.1155/2016/6848902 · Cited by 21
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma—A Unique Entity
Germans, S. K., Kulak, O., Koduru, P. R. K., Oliver, D., Gagan, J., Patel, P. A., Anderson, L. D., Fuda, F. S., Chen, W., & Jaso, J. M. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa109 · Cited by 22
Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
Nadiminti, K. V. G., Sidiqi, M. H., Meleveedu, K. S., Alkhateeb, H. B., Hogan, W. J., Litzow, M. R., Patnaik, M. M., Kumar, S. K., Gertz, M. A., Chen, D., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00454-y · Cited by 21
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
Miyamoto, T., Yoshimoto, G., Kamimura, T., Muta, T., Takashima, S., Ito, Y., Shiratsuchi, M., Choi, I., Kato, K., Takenaka, K., et al. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1402-0 · Cited by 21
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
Mark, T. M., Coleman, M., & Niesvizky, R. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.008 · Cited by 21
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis
Boyle, E. M., Fouquet, G., Manier, S., Gauthier, J., Noel, M. P., Borie, C., Facon, T. T. F., Elalamy, I., & Leleu, X. P. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.52 · Cited by 21
Self-citation
Perspectives in the treatment of multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 22
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019
Giannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 22
Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
Gupta, N., Labotka, R., Liu, G., Hui, A., & Venkatakrishnan, K. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0346-7 · Cited by 21
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
Costa, L. J., Landau, H. J., Chhabra, S., Hari, P., Innis-Shelton, R. D., Godby, K. N., Hamadani, M., Tamari, R., Anderton, K., Dixon, P. M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.036 · Cited by 21
Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
Jackson, G. H., Galinsky, J., Alderson, D., D’Souza, V., Buchanan, V., Dhanasiri, S., & Walker, S. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13298 · Cited by 21
Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses
Phan, V. T. X., Ito, T., Inaba, M., Azuma, Y., Kibata, K., Inagaki‐Katashiba, N., Tanaka, A., Satake, A., & Nomura, S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001410 · Cited by 21
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma
Qiao, S.-K., Guo, X., Ren, J., & Ren, H. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156134 · Cited by 23
Advances in multiple myeloma therapy during two past decades
Špıčka, I. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.05.005 · Cited by 20
Myeloma: management of the newly diagnosed high-risk patient
Dispenzieri, A. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.485 · Cited by 20
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
Besson, L., Charrier, E., Karlin, L., Allatif, O., Marçais, A., Rouzaire, P., Belmont, L., Attal, M., Lombard, C., Salles, G. A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00704 · Cited by 20
Self-citation
Multiple Myeloma: Updates on Diagnosis and Management.
Jewell, S. W., Xiang, Z., Kunthur, A., & Mehta, P. (2015) · Europe PMC (PubMed Central) · Cited by 20
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival
Charalampous, C., Goel, U., Kapoor, P., Binder, M., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Fonder, A. L., Gertz, M. A., Gonsalves, W. I., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26806 · Cited by 20
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
Sborov, D. W., Benson, D. M., Williams, N., Huang, Y., Bowers, M. A., Humphries, K., Efebera, Y. A., Devine, S. M., & Hofmeister, C. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13527 · Cited by 20
Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients
Waal, E. G. M. D., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A. W. G., Tromp, Y., Vellenga, E., & Hovenga, S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13653 · Cited by 20
Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients
Michallet, M., Sobh, M., Cheikh, J. E., Morisset, S., Sîrvent, A., Reman, O., Cornillon, J., Tabrizi, R., Milpied, N. J., Harousseau, J., et al. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.08.003 · Cited by 20
Self-citation
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective
Hübel, K., de la Rubia, J., Azar, N., & Corradini, P. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12362 · Cited by 20
Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QT c Intervals in the Thorough QT c Study Conducted in Healthy Men
Chen, N., Ye, Y., Liu, L., Reyes, J. F., Assaf, M. S., Kasserra, C., Zhou, S. Y., & Palmisano, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12081 · Cited by 20
Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
Giagounidis, A. A. N. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.07.001 · Cited by 20
Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
Maïga, S., Gomez‐Bougie, P., Bonnaud, S., Gratas, C., Moreau, P., Gouill, S. L., Pellat‐Deceunynck, C., & Amiot, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.186 · Cited by 20
Self-citation
Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis
Clave, E., Douay, C., Coman, T., Busson, M., Bompoint, C., Moins‐Teisserenc, H., Glauzy, S., Carmagnat, M., Gorin, N. C., Toubert, A., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.865182 · Cited by 21
Self-citation

Authors: Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.-C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., & Harousseau, J.-L.
Affiliations: Hôpital Purpan (FR)
CHU Dijon Bourgogne (FR)
Hôpital Claude Huriez (FR)
Institut Paoli-Calmettes (FR)
Centre Hospitalier Régional et Universitaire de Nancy (FR)
Hôpital Saint-Antoine (FR)
Hôpital Pontchaillou (FR)
Centre Hospitalier Universitaire Vaudois (CH)
Centre Hospitalier Universitaire de Besançon (FR)
Hôpital Edouard Herriot (FR)
Institut Curie (FR)
ORCID: Attal, Michel
Caillot, Denis
Moreau, Philippe
Facon, Thierry
Hulin, Cyrille
Garderet, Laurent
Decaux, Olivier
Leyvraz, Serge
Vekemans, Marie-Christiane
Michallet, Mauricette
Dumontet, Charles
Roussel, Murielle
Leleu, Xavier
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1782-1791
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114138
OpenAlex: W2128084036
Semantic Scholar: c28c0ef900dcfd0347dbf26ecd97d5547f948a9a
Cited by: 1,155
References: 24
Citations by year: 2026: 32 · 2025: 36 · 2024: 43 · 2023: 61 · 2022: 70 · 2021: 85 · 2020: 79 · 2019: 68 · 2018: 83 · 2017: 98 · 2016: 108 · 2015: 86 · 2014: 102 · 2013: 133 · 2012: 68
FWCI: 82.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords: lenalidomide, maintenance therapy, multiple myeloma, autologous stem cell transplantation, progression-free survival, event-free survival, secondary malignancies, peripheral neuropathy, young patients, residual disease
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Kaplan-Meier Estimate, Young Adult, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks